A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer

NCT02083185 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

136

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Relugolix
DRUG: Leuprorelin

Sponsor

Millennium Pharmaceuticals, Inc.